Rating for ZLAB
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Benzinga
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in ChinaBusiness Wire
- Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung CancerBusiness Wire
- Zai Lab Limited (NASDAQ: ZLAB) had its price target raised by analysts at JPMorgan Chase & Co. from $38.00 to $44.00. They now have an "overweight" rating on the stock.MarketBeat
- Zai Lab Announces Participation in November and December Investor ConferencesBusiness Wire
ZLAB
Earnings
- 8/6/24 - Miss
ZLAB
Sec Filings
- 11/8/24 - Form SC
- 11/5/24 - Form 4
- 11/4/24 - Form 144
- ZLAB's page on the SEC website